A Multicenter Phase II trial of TS-1/oxaliplatin (SOX) +bevacizumab in patients with unresectable advanced/metastatic colorectal cancer (HiSCO-02)
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2620419
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Patients receive infusional oxaliplatin, bevacizumab, and oral TS-1 every 21 days.
Primary outcome(s): Response rate
Study Design: Single arm Non-randomized
创建时间：
2011-03-15
